Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory ...

In collaboration with Gavi, Pfizer has been instrumental in expanding access to lifesaving vaccines in low- and ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.

The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...

A year after the first samRNA vaccine approval, experts say others are likely to face scientific and regulatory hurdles.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...